---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-067791"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T01:11:29.010312+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Phase 2 XPro trial misses primary endpoint; positive subpopulation data at AAIC

## Summary
- Primary endpoint not met in mITT group; 208 early-AD participants with inflammation biomarkers.
- Consistent benefit seen in subpopulation with Aβ pathology and ≥2 inflammatory biomarkers.
- Oral presentation at AAIC on July 29, 2025 at 2:00-3:30 PM ET in Toronto.
- Company seeking strategic partnership to accelerate XPro development for Alzheimer's.
- Publication of full results anticipated by mid-August 2025.

## SEC filing metadata
- accession: 0001213900-25-067791
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025067791/0001213900-25-067791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025067791/ea0250327-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-067791
- JSON: https://secwatch.observer/filing/0001213900-25-067791.json
- Plain text: https://secwatch.observer/filing/0001213900-25-067791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.